Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials

ClinicalLIVEUpdated 18 Nov 2026

New Clinical Trials

Clinical trials companies registered in the last 30 days, worldwide, with the sponsor, phase and countries.

Sources: ClinicalTrials.gov · Rebuilt weekly · Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase.

Trials
777
in the 30 days to 2026-11-18
Added in 30 days
777
to 18 Nov 2026
Top country
United States
192 · 25% of the list
Phase covered
8
distinct values
Snapshot · 18 Nov 2026
Explore all 777

Signals

What the register says this week, and why it matters if you sell into it.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
  3. 174 of the listed studies are device, diagnostic or digital-health studies (no drug phase).
  4. A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

Export the full new clinical trials

777 rows as a .csv. Free. Every field, with its source link.

Country
Phase 1
Study type
53 / 777 trials
PostedSponsorStudyPhaseStatus
18 Nov 2026Coherus Oncology, Inc.United StatesA Study of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid TumorsPhase 1, Phase 2Recruiting18 Nov 2026Diabetes Free, Inc.GermanyDual-targeting of B & T Cell Pathways Evaluation TrialPhase 1, Phase 2Recruiting18 Nov 2026Frontier Medicines CorporationPh 1/2 Study to Evaluate Safety & Tolerability of FMC-242 Alone and in Combination in Adults With Advanced Solid TumorsPhase 1, Phase 2Not Yet Recruiting18 Nov 2026GlaxoSmithKlineA Study of GSK5864399 Administered Alone or in Combination With Other Anti-cancer Agents in Participants With Solid TumoursPhase 1, Phase 2Not Yet Recruiting18 Nov 2026IpsenA Phase I/II Study to Learn About the Safety and Effects of a New Medicine Called IPN60350 Alone or in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Solid TumorsPhase 1, Phase 2Not Yet Recruiting17 Nov 2026Actithera INC.177Lu-ACT319 in FAP Expressing Solid TumorsPhase 1, Phase 2Not Yet Recruiting17 Nov 2026Novo Nordisk A/SUnited StatesA Research Study of a New Medicine NNC0662-3168 for Weight Management and Type 2 DiabetesPhase 1, Phase 2Not Yet Recruiting17 Nov 2026SensorionFranceA Clinical Trial With SENS-601, Injected With SPHYNX Administration System, in the Pediatric Population Presenting With Hearing Loss Related to Pathogenic Variation(s) of GJB2 GenePhase 1, Phase 2Recruiting16 Nov 2026Bristol-Myers SquibbUnited States, CanadaA Study of BMS-986548 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid MalignanciesPhase 1, Phase 2Not Yet Recruiting16 Nov 2026Chengdu Suncadia Medicine Co., Ltd.ChinaA Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-9308 Tablet as Monotherapy or Combination Therapy in Participants With Advanced Solid TumorsPhase 1, Phase 2Not Yet Recruiting16 Nov 2026CStone PharmaceuticalsAustralia, ChinaA First-in-human (FIH), Open-label, and Multi-center Study of CS5006 in Participants With Advanced Solid TumorsPhase 1, Phase 2Not Yet Recruiting16 Nov 2026Kanglin Biotechnology (Hangzhou) Co., Ltd.ChinaGene Therapy of Parkinson's Disease With KL002 in a Phase 1/2a Clinical StudyPhase 1, Phase 2Not Yet Recruiting16 Nov 2026Shanghai Mabgeek Biotech.Co.LtdChinaMG-K10 in Pediatric Atopic Dermatitis (6-12 Years)Phase 1, Phase 2Not Yet Recruiting16 Nov 2026TuHURA Biosciences, Inc.A Study of TBS-2025 Monotherapy in Participants With r/r NPM1mut AMLPhase 1, Phase 2Not Yet Recruiting13 Nov 2026CAMP4 Therapeutics CorporationArgentinaStudy of CMP-002 in Participants With SYNGAP1-Related DisorderPhase 1, Phase 2Not Yet Recruiting13 Nov 2026Changchun GeneScience Pharmaceutical Co., Ltd.ChinaClinical Trial of GenSci136 in Patients With Myasthenia GravisPhase 1, Phase 2Not Yet Recruiting12 Nov 2026AstraZenecaA Modular, Phase I/II Study to Evaluate CT204V-CD19 x CD20 in Participants With Relapsed or Refractory B-Cell Malignancies.Phase 1, Phase 2Not Yet Recruiting12 Nov 2026Novelty Nobility, Inc.ChinaA Study of NN2802, an Anti-c-Kit Antibody, in Healthy Participants and in Adults With Chronic Spontaneous Urticaria (CSU)Phase 1, Phase 2Recruiting12 Nov 2026Qilu Pharmaceutical Co., Ltd.ChinaPhase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid TumorsPhase 1, Phase 2Not Yet Recruiting12 Nov 2026Txinno Bioscience Inc.South KoreaPhase 1b/2 to Evaluate the Safety, Tolerability, and Efficacy of TXN10128 in Combination With TOPO-I Inhibitor-based Therapies (Irinotecan or TROP2 ADC) in Advanced or Metastatic EGFR Mutated NSCLCPhase 1, Phase 2Recruiting10 Nov 2026Kanglin Biotechnology (Hangzhou) Co., Ltd.United StatesA Phase 1/2a Clinical Study of KL002 in Treatment of Parkinson's DiseasePhase 1, Phase 2Not Yet Recruiting10 Nov 2026Minghui Pharmaceutical (Shanghai) LTDChinaA Clinical Study of MHB034C for Injection in Participants With Advanced Solid TumorsPhase 1, Phase 2Not Yet Recruiting6 Nov 2026Dartsbio Pharmaceuticals Ltd.AustraliaPhase 1/2 Study of DS010 in Advanced Cancer Patients With CachexiaPhase 1, Phase 2Recruiting6 Nov 2026Viatris Inc.United StatesA Phase 1/2 Clinical Trial to Evaluate the Safety and Efficacy of MR-146 in Subjects With Stage I and Stage II Neurotrophic KeratopathyPhase 1, Phase 2Recruiting5 Nov 2026Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.ChinaClinical Trial of Recombinant Herpes Zoster Vaccine (ZFA01 Adjuvant, CHO Cells)Phase 1, Phase 2Recruiting4 Nov 2026Genfleet Therapeutics (Shanghai) Inc.A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal CancerPhase 1, Phase 2Not Yet Recruiting3 Nov 2026Beijing Mabworks Biotech Co., Ltd.A Study of MBS314 for Injection in Participants With Relapsed/Refractory Multiple Myeloma.Phase 1, Phase 2Not Yet Recruiting3 Nov 2026CSPC ZhongQi Pharmaceutical Technology Co., Ltd.ChinaA Study of SYH2051 in Combination With Irinotecan Hydrochloride Liposome Injection in Subjects With Advanced Solid TumorsPhase 1, Phase 2Not Yet Recruiting3 Nov 2026Ensem TherapeuticsUnited StatesA KRAS Inhibitor in Participants With Advanced Solid TumorsPhase 1, Phase 2Recruiting3 Nov 2026Metagen Therapeutics, Inc.United States, JapanSafety, Dosage, and Microbiome Engraftment Study of MGT-006 for Ulcerative Colitis (ROOT Study)Phase 1, Phase 2Recruiting2 Nov 2026Crescent Biopharma, Inc.United StatesCR-002 in Adult Participants With Locally Advanced or Metastatic Solid TumorsPhase 1, Phase 2Recruiting2 Nov 2026Merck Sharp & Dohme LLCMK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A)Phase 1, Phase 2Not Yet Recruiting29 Oct 2026Cytogel Pharma, LLCUnited StatesA Study of CYT-1010 in Healthy Volunteers and Participants With Acute Pain After Third Molar ExtractionPhase 1, Phase 2Recruiting28 Oct 2026Beijing InnoCare Pharma Tech Co., Ltd.ChinaEvaluation of ICP-B381 in Patients With Advanced Solid TumorsPhase 1, Phase 2Recruiting28 Oct 2026CytomX TherapeuticsStudy of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal CancerPhase 1, Phase 2Not Yet Recruiting28 Oct 2026Paulex Bio Inc.Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAL-119 in Healthy Volunteers and Adult Participants With Type 1 or Type 2 DiabetesPhase 1, Phase 2Not Yet Recruiting28 Oct 2026Shanghai Huaota Biopharmaceutical Co., Ltd.ChinaA Study of HB0056 in Adult Participants With Moderate to Severe AsthmaPhase 1, Phase 2Recruiting28 Oct 2026Siren BiotechnologyA Study of SRN-101 Gene Therapy in Adults With Recurrent High-Grade Glioma (ALERT-1)Phase 1, Phase 2Not Yet Recruiting27 Oct 2026CSPC Megalith Biopharmaceutical Co.,Ltd.A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SYS6062 in Patients With Advanced Solid Tumors.Phase 1, Phase 2Not Yet Recruiting27 Oct 2026Grand Theravac Life Sciences (Hangzhou) Co., Ltd.A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB)Phase 1, Phase 2Not Yet Recruiting27 Oct 2026GuangZhou Cellgenes Biotechnology Co., Ltd.ChinaSafety and Efficacy of CG-BM1 in Ischemic StrokePhase 1, Phase 2Recruiting27 Oct 2026Medsyn Biopharma, LLCA Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid TumorsPhase 1, Phase 2Not Yet Recruiting27 Oct 2026Tango Therapeutics, Inc.TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC PatientsPhase 1, Phase 2Not Yet Recruiting26 Oct 2026Editas Medicine, Inc.AustraliaEDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C)Phase 1, Phase 2Not Yet Recruiting23 Oct 2026CSPC Megalith Biopharmaceutical Co.,Ltd.Immunogenicity and Safety of SYS6052 in the Participants Aged 40 Years and AbovePhase 1, Phase 2Not Yet Recruiting23 Oct 2026DaniscoCanadaA Study of Single and Combination Lipase Dietary Supplements to Increase Fatty Acid Absorption in Generally Health AdultsPhase 1, Phase 2Not Yet Recruiting23 Oct 2026Keymed Biosciences Co.LtdChinaStudy of CM529D1 in Participants With Advanced Solid TumorsPhase 1, Phase 2Not Yet Recruiting22 Oct 2026Daiichi SankyoTaiwanA Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]Phase 1, Phase 2Recruiting22 Oct 2026Serum Institute of India Pvt. Ltd.AustraliaClinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 Valent Human Papillomavirus Virus (10vHPV) VaccinePhase 1, Phase 2Not Yet Recruiting21 Oct 2026BioNTech SEA Clinical Trial to Test if the Investigational Drug BNT3210 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker Sialyl-TnPhase 1, Phase 2Not Yet Recruiting

// How AOS uses this

Every row here is a potential account. AOS finds the ones that need what you sell, maps the decision makers and prepares the outreach for your approval.